Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI

Pietro Zara; Valentina Floris; Eoin P. Flanagan; A. Sebastian Lopez-Chiriboga; Brian G. Weinshenker; Paolo Solla; Elia Sechi

doi:10.1177/20552173211048761

Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI

Pietro Zara, Valentina Floris, Eoin P. Flanagan, A. Sebastian Lopez-Chiriboga, Brian G. Weinshenker, Paolo Solla, Elia Sechi

Neurology

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Myelin-oligodendrocyte-glycoprotein (MOG)-IgG-positivity in patients with typical MS lesions on MRI may lead to diagnostic/therapeutic uncertainty. Objective and Methods: We reviewed reports of cases with MS phenotype on MRI and MOG-IgG-positivity published in Pubmed between 01/2012-06/2021. Results: Sixteen patients were included (median age [range], 37,5 [25-66] years; 60% female). Three patients initially tested negative for MOG-IgG. Disease course was: relapsing-remitting, 10; or progressive, 6. Intrathecal IgG-synthesis was common (79%). Low and high-efficacy MS-targeted agents prevented relapses in 30% and 100%, respectively. None of the patients showed resolution of MRI T2-lesions over time. Conclusions: MOG-IgG-positivity is unlikely to alter the expected treatment response and outcomes in patients with otherwise typical MS phenotype on MRI.

Original language	English (US)
Journal	Multiple Sclerosis Journal - Experimental, Translational and Clinical
Volume	7
Issue number	4
DOIs	https://doi.org/10.1177/20552173211048761
State	Published - 2021

Keywords

MOG-IgG
MOGAD
MS
NMOSD
false positive

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1177/20552173211048761

Cite this

@article{0d2130995014428386de32b26dbe1d1e,

title = "Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI",

abstract = "Background: Myelin-oligodendrocyte-glycoprotein (MOG)-IgG-positivity in patients with typical MS lesions on MRI may lead to diagnostic/therapeutic uncertainty. Objective and Methods: We reviewed reports of cases with MS phenotype on MRI and MOG-IgG-positivity published in Pubmed between 01/2012-06/2021. Results: Sixteen patients were included (median age [range], 37,5 [25-66] years; 60% female). Three patients initially tested negative for MOG-IgG. Disease course was: relapsing-remitting, 10; or progressive, 6. Intrathecal IgG-synthesis was common (79%). Low and high-efficacy MS-targeted agents prevented relapses in 30% and 100%, respectively. None of the patients showed resolution of MRI T2-lesions over time. Conclusions: MOG-IgG-positivity is unlikely to alter the expected treatment response and outcomes in patients with otherwise typical MS phenotype on MRI.",

keywords = "MOG-IgG, MOGAD, MS, NMOSD, false positive",

author = "Pietro Zara and Valentina Floris and Flanagan, {Eoin P.} and Lopez-Chiriboga, {A. Sebastian} and Weinshenker, {Brian G.} and Paolo Solla and Elia Sechi",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2021.",

year = "2021",

doi = "10.1177/20552173211048761",

language = "English (US)",

volume = "7",

journal = "Multiple Sclerosis Journal - Experimental, Translational and Clinical",

issn = "2055-2173",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI

AU - Zara, Pietro

AU - Floris, Valentina

AU - Flanagan, Eoin P.

AU - Lopez-Chiriboga, A. Sebastian

AU - Weinshenker, Brian G.

AU - Solla, Paolo

AU - Sechi, Elia

N1 - Publisher Copyright: © The Author(s), 2021.

PY - 2021

Y1 - 2021

N2 - Background: Myelin-oligodendrocyte-glycoprotein (MOG)-IgG-positivity in patients with typical MS lesions on MRI may lead to diagnostic/therapeutic uncertainty. Objective and Methods: We reviewed reports of cases with MS phenotype on MRI and MOG-IgG-positivity published in Pubmed between 01/2012-06/2021. Results: Sixteen patients were included (median age [range], 37,5 [25-66] years; 60% female). Three patients initially tested negative for MOG-IgG. Disease course was: relapsing-remitting, 10; or progressive, 6. Intrathecal IgG-synthesis was common (79%). Low and high-efficacy MS-targeted agents prevented relapses in 30% and 100%, respectively. None of the patients showed resolution of MRI T2-lesions over time. Conclusions: MOG-IgG-positivity is unlikely to alter the expected treatment response and outcomes in patients with otherwise typical MS phenotype on MRI.

AB - Background: Myelin-oligodendrocyte-glycoprotein (MOG)-IgG-positivity in patients with typical MS lesions on MRI may lead to diagnostic/therapeutic uncertainty. Objective and Methods: We reviewed reports of cases with MS phenotype on MRI and MOG-IgG-positivity published in Pubmed between 01/2012-06/2021. Results: Sixteen patients were included (median age [range], 37,5 [25-66] years; 60% female). Three patients initially tested negative for MOG-IgG. Disease course was: relapsing-remitting, 10; or progressive, 6. Intrathecal IgG-synthesis was common (79%). Low and high-efficacy MS-targeted agents prevented relapses in 30% and 100%, respectively. None of the patients showed resolution of MRI T2-lesions over time. Conclusions: MOG-IgG-positivity is unlikely to alter the expected treatment response and outcomes in patients with otherwise typical MS phenotype on MRI.

KW - MOG-IgG

KW - MOGAD

KW - MS

KW - NMOSD

KW - false positive

UR - http://www.scopus.com/inward/record.url?scp=85120418513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120418513&partnerID=8YFLogxK

U2 - 10.1177/20552173211048761

DO - 10.1177/20552173211048761

M3 - Article

AN - SCOPUS:85120418513

SN - 2055-2173

VL - 7

JO - Multiple Sclerosis Journal - Experimental, Translational and Clinical

JF - Multiple Sclerosis Journal - Experimental, Translational and Clinical

IS - 4

ER -

Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this